Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Cabozantinib (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CaboMAb
- 13 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 10 Jun 2017 Biomarkers information updated
- 29 Apr 2017 Planned number of patients changed from 30 to 50.